Previous 10 | Next 10 |
home / stock / aps:cc / aps:cc news
SAN DIEGO and TORONTO, June 26, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies,...
Finalized Dose Escalation/Dose Exploration Trial in 77 R/R AML Patients Favorable safety with monotherapy responses across four dose levels with no DLT in mutationally diverse and difficult to treat R/R AML Populations TP53 MUT CR/CRh = 20% │ RAS MUT C...
SAN DIEGO and TORONTO, June 05, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, a...
SAN DIEGO and TORONTO, May 31, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancie...
SAN DIEGO and TORONTO, May 25, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, to...
SAN DIEGO and TORONTO, May 23, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, an...
─ Tuspetinib Dose Escalation and Dose Exploration Trial Completed and Delivered Clinical Responses as Monotherapy Over Four Dose Levels in Very Difficult to Treat AML Patient Populations ─ ─ Doublet of Tuspetinib and Venetoclax Dosing Underway for Relapsed/Ref...
SAN DIEGO and TORONTO, May 04, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, Pr...
SAN DIEGO and TORONTO, April 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the first quarter end...
2023-04-12 15:02:41 ET Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide si...
News, Short Squeeze, Breakout and More Instantly...
Aptose Biosciences Inc. Company Name:
APS:CC Stock Symbol:
TSXC Market:
Aptose Biosciences Inc. Website:
SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, t...
A look at the top 10 most actives in Canada BetaPro Natural Gas Leveraged Daily Bull ETF (HNU) fell 11.1% to $2.63 on volume of 13,371,978 shares Baytex Energy Corp. (BTE) fell 1.4% to $5.08 on volume of 13,132,263 shares Enbridge Inc. (ENB) rose 0.7% to $49.58 on volume of 10,761,843 sha...
A look at the top 10 most actives in Canada Calibre Mining Corp. (CXB) fell 2.9% to $1.835 on volume of 79,684,444 shares Canadian Natural Resources Limited (CNQ) rose 1.6% to $48 on volume of 6,456,525 shares Alaris Equity Partners Income Trust 5.50% convertible unsecured subordinated de...